Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal gland with a poor prognosis, especially in metastatic stages, with a 5 year overall survival of 0% to 15%, depending on the series. ACC presents with symptoms caused by hormone production (glucocorticoids, androgens, mineralocorticoids, or estrogens) in ∼60% of the cases \[[@B1]\].

On the contrary, peptide oversecretion has rarely been reported. Because the insulin-like growth factor 2 (*IGF2*) gene is overexpressed in must sporadic ACCs, circulating levels of IGF2 were quantified in patients with adrenal tumors. However, these levels were similar in benign and malignant adrenal tumors and showed no correlation with overall or progression-free survival \[[@B2]\]. In exceptional cases, ACCs can produce and secrete big-IGF2, leading to hypoglycemia, as reported in 1 out of 78 patients with non--islet cell tumor hypoglycemia \[[@B3]\].

Hofland *et al.* \[[@B4]\] found that the serum inhibin pro-*α*C might be a helpful diagnostic tool to discriminate ACCs from benign adrenal tumors and might serve as a tumor marker for ACCs during treatment follow-up. Inhibin pro-*α*C is the precursor form of inhibin *α*-subunit (encoded by *INHA*). Inhibin A and B are 2 dimeric peptidic hormones belonging to the transforming growth factor-*β* family and consist of the common *α*-subunit dimerized with a *β*-subunit (*β*A-subunit for inhibin A and *β*B-subunit for inhibin B). *β*-Subunits are ubiquitously expressed, whereas the *α*-subunit is only expressed in the ovary, testis, placenta, and adrenal cortex \[[@B5]\]. Circulating inhibin B comes from gonad and negatively regulates the pituitary follicle-stimulating hormone (FSH) secretion \[[@B6]\].

In this study, we describe the case of a patient presenting with an ACC and a blunted FSH related to a tumoral secretion of inhibin B, which was reversed after chemotherapy.

1. Case Presentation {#s4}
====================

A 60-year-old man had been admitted to the hospital for a right intermittent abdominal pain for 1 week. The computed tomography showed a retroperitoneal mass (145 × 100 mm) associated with peritoneal and lung metastases and pulmonary hilar lymph nodes \[[Fig. 1(A)](#F1){ref-type="fig"}\]. The patient was transferred to the endocrine unit. His previous medical history included hypertension that was treated in the last year by β-blocker, spironolactone, and thiazide diuretic. The magnetic resonance imaging was in favor of an adrenal mass and showed a venous tumor thrombus in vena cava and in renal vein. ^18^F-fluorodeoxyglucose positron emission tomography showed an uptake of the retroperitoneal mass (standardized uptake value maximum adrenal/liver ratio of 3.7), the peritoneal metastases, and the pulmonary hilar lymph nodes, suggesting a malignant tumor \[[Fig. 1(B)](#F1){ref-type="fig"}\]. Clinically, there was no evidence of Cushing syndrome and no alteration of general conditions. Hormonal investigation showed ACTH-independent hypercortisolism with a suppressed ACTH \< 2 pmol/L (range, 2 to 13) and 24 hours urinary-free cortisol at 441 nmol/24 h (range, 69 to 248). Surprisingly, the follicle stimulating hormone (FSH) levels were suppressed (0.14 IU/L; normal, 1 to 12) and remained blunted during gonadotropin-releasing hormone (GnRH) stimulation, whereas basal (3.7 IU/L; normal, 0.8 to 12) and stimulated luteinizing hormone (LH) levels were normal ([Fig. 2](#F2){ref-type="fig"}). To explain this dissociation between low FSH levels and normal LH levels, measurement of inhibin B was performed and revealed very high levels (1100 pg/mL; normal, 28 to 294). Estradiol (168.5 pmol/L; normal, 36 to 220), testosterone (13.3 nmol/L; normal, 8.3 to 34.5), dehydroepiandrosterone sulfate (4.9 µmol/L; normal, 4.5 to 8.5), 17-hydroxyprogesterone (13.5 nmol/L; normal, 8.3 to 34.5), and inhibin A (2 pg/mL; normal, 0.5 to 2.5) levels were normal. Given the atypical hormonal findings, a percutaneous mass biopsy was performed to have a pathological diagnosis. Immunohistochemistry showed a strong nuclear staining for steroidogenic factor-1, favoring the diagnosis of adrenocortical tumor. Labeling of ACC sections with an anti-inhibin *α*-subunit antibody revealed an intense and diffuse immunostaining consistent with the high inhibin B levels \[[Fig. 1(C)](#F1){ref-type="fig"}\]. Given the metastatic disease (European Network for the Study of Adrenal Tumors stage 4), the patient was treated with mitotane and chemotherapy (etoposide and cisplatin), in agreement with the international recommendation \[[@B1]\]. After 2 cycles, although mitotane levels were not yet in the therapeutic range (7.56 mg/L, therapeutic levels \> 14 mg/L), inhibin B levels dropped (15 pg/mL). After 5 cycles, both the ACC and the pulmonary hilar lymph node sizes were reduced by 15%, suggesting a stabilization of the disease. Inhibin B levels remained low (10 pg/mL) and basal and GnRH-stimulated FSH levels were normalized ([Fig. 2](#F2){ref-type="fig"}). The patient underwent a tumor resection and the pathology confirmed the ACC diagnosis (Weiss score of 9), with positive steroidogenic factor-1 immunostaining. The intensity of the *α*-inhibin subunit immunostaining was significantly decreased and showed a different pattern than the one observed in the earlier biopsy \[[Fig. 1(D)](#F1){ref-type="fig"}\].

![(A) Computed tomography scan at diagnosis showing a retroperitoneal mass (145 × 100 mm) (white dotted line). (B) ^18^F-fluorodeoxyglucose positron emission tomography before mitotane and chemotherapy showing an uptake localized to pulmonary hilar lymph nodes (green arrows) and retroperitoneal mass with a maximum standardized uptake value of 10.2 and an adrenal/liver maximum standardized uptake value ratio of 3.7 (red arrow). (C) Biopsy: *α*-inhibin subunit immunostaining of the retroperitoneal mass (original magnification, ×20). (D) *α*-Inhibin subunit immunostaining of adrenal mass after surgery (original magnification, ×20).](js-01-46-f1){#F1}

![GnRH stimulation test: FSH response (red line) and LH response (blue line) at initial evaluation (solid line) and after chemotherapy (dotted line).](js-01-46-f2){#F2}

2. Discussion {#s5}
=============

In this study, we report a case of an inhibin B--secreting ACC with complete normalization of inhibin levels after chemotherapy. Inhibin B hypersecretion leading to selective FSH suppression was previously documented in 2 patients with adrenocortical tumor: a 39-year-old man presenting with a feminizing adrenocortical adenoma \[[@B7]\], and a 30-year-old man presenting with an ACC causing abdominal pain and loss of libido \[[@B8]\]. In both cases, immunohistochemistry showed positive *α*-inhibin staining \[[@B7]\]. In these 2 male patients, the high inhibin B levels were associated with high estradiol \[[@B7]\] and estrone levels \[[@B7]\], whereas in the case described in this study, estradiol and testosterone were both normal. In the previous 2 cases, inhibin B levels were 1.5- to 2-fold above the upper limit of normal, whereas in this case the levels were 4.5-fold above the upper limit of normal. These observations suggest that inhibin B hypersecretion is sufficient to inhibit FSH, independently of estradiol and testosterone, and that inhibin B is the main physiologic negative feedback regulator of FSH secretion \[[@B8]\].

Secretion of inhibin B by ACCs may be underdiagnosed and underreported. Indeed, Hofland *et al.* \[[@B4]\] showed an increase of inhibin B in 3 out of 9 ACCs and an increase of inhibin pro-*α*C in 59% among 32 studied ACCs, whereas inhibin A was never increased, as observed in the present case. In this study, the observed decrease of inhibin pro-*α*C levels after surgery or mitotane led the authors to suggest using this peptide as a tumor marker during treatment and follow-up of ACCs.

This case illustrates disease stabilization after mitotane and chemotherapy treatment, associated with a decrease in serum inhibin B levels. Interestingly, the decrease in circulating inhibin B levels was associated with a decrease of *α*-inhibin subunit immunostaining in the resected carcinoma, compared with the biopsy.

A tumoral elevation of serum inhibin B is mainly observed in ovarian tumors. An inhibin B increase is detected in ∼90% of granulosa cell tumors (stromal sex-cord tumors) and in 60% of mucinous cystadenocarcinoma (epithelial ovarian tumors). Inhibin is less frequently increased in nonmucinous epithelial tumors (elevation of total inhibin in 15% to 35%). Some cases of Sertoli cell tumors may present an inhibin B hypersecretion, which correlates with a poor prognosis and a high risk of recurrence \[[@B9]\].

3. Conclusion {#s6}
=============

A decrease of FSH levels with normal LH levels should evoke inhibin B secretion in the context of an adrenal tumor. In this study, we report treatment of an ACC with a combination of chemotherapy and mitotane that leads to a decrease of inhibin B levels, a normalization of basal and stimulated FSH levels, as well as a reduction in tumor volume.
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